Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
102 USD | +0.01% | +7.11% | +2.00% |
13/05 | Legend Biotech 1Q Loss Narrows with Higher Carvykti Sales | DJ |
10/05 | Novartis’ Scemblix Gets Third US FDA Breakthrough Therapy Designation | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Sales forecast by analysts have been recently revised upwards.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- With an enterprise value anticipated at 4.14 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.00% | 208B | - | ||
+29.98% | 684B | C+ | ||
+30.34% | 568B | B | ||
-3.52% | 361B | C+ | ||
+18.59% | 329B | B- | ||
+4.07% | 284B | C+ | ||
+16.21% | 240B | B+ | ||
-6.83% | 200B | A+ | ||
+7.09% | 166B | C+ | ||
-1.22% | 159B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- NOVN Stock
- NVSEF Stock
- Ratings Novartis AG